Rivanicline hemioxalate

Rivanicline (RJR-2403) hemioxalate is a neuronal nicotinic receptor agonist. Rivanicline hemioxalate is highly selective for the rat brain cortex nAChRs (Ki = 26 nM, EC50 of 732 nM) and α4β2 subtype (Ki = 26 nM, EC50 = 16 μM) . Rivanicline hemioxalate can significantly restore the learning impairment and cognitive dysfunction. Rivanicline hemioxalate can be used for the study of neurodegenerative diseases (such as schizophrenia or Alzheimer's disease) [1][2][3][4][5].

Product Specifications

Product Name Alternative

RJR-2403 (hemioxalate) ; (E) -Metanicotine (hemioxalate)

UNSPSC

12352211

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/RJR-2403-hemioxalate.html

Purity

95.0

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

CNCC/C=C/C1=CC=CN=C1.OC(C(O)=O)=O.[0.5]

Molecular Formula

C11H15N2O2

Molecular Weight

207.23

References & Citations

[1]Bencherif M, et al. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J Pharmacol Exp Ther. 1996 Dec;279 (3) :1413-21.|[2]Lippiello PM, et al. RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization. J Pharmacol Exp Ther. 1996 Dec;279 (3) :1422-9.|[3]Damaj MI, et al. Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. J Pharmacol Exp Ther. 1999 Oct;291 (1) :390-8.|[4]Papke RL, et al The activation and inhibition of human nicotinic acetylcholine receptor by RJR-2403 indicate a selectivity for the alpha4beta2 receptor subtype. J Neurochem. 2000 Jul;75 (1) :204-16. |[5]Rodríguez-Moreno A, et al. The nicotinic agonist RJR-2403 compensates the impairment of eyeblink conditioning produced by the noncompetitive NMDA-receptor antagonist MK-801. Neurosci Lett. 2006 Jul 10;402 (1-2) :102-7.